at Healthone, Denver, CO, United States; 3START-Midwest, Grand Rapids, MI, United States; 4Jounce Therapeutics, Cambridge, MA, United States; 5Florida Cancer Specialists – SCRI, Sarasota, FL, United States Correspondence: Kyriakos Papadopoulos (Kyri
at Healthone, Denver, CO, United States; 3START-Midwest, Grand Rapids, MI, United States; 4Jounce Therapeutics, Cambridge, MA, United States; 5Florida Cancer Specialists - SCRI, Sarasota, FL, United States Correspondence: Kyriakos Papadopoulos (Kyri.Papadopoulos@startsa.com) Background JTX-4014 is a fully human mAb consisting of 2 identical hinge-stabilized immunoglobulin gamma 4 (IgG4, S228P) heavy and two identical kappa (Ig) light chains, that specifically binds to PD-1. a preliminary cohort of 10 patients using qmIF, excluding patients with viral hepatitis. FFPE tumor sections were pre-selected by a GI pathologist. Slides were stained using qmIF for MPO (PMNs), CD3 (T cells), CD8 (cytotoxic T cells), CD68 (macrophages), HLA-DR (immune activation), and Hep-Par1 (hepatocytes/tumor). Multiplex images were visualized using Vectra (Akoya) and processed using inForm (Akoya). Data was analyzed using R Studio for concatenation, density, nearest neighbor and…